|
|
|
|
Department of Pharmacology, Biozentrum, University of Basel, CH-4056 Basel, Switzerland (F.W.F, U.A.M.); and Dr. Margarete Fischer-Bosch Institut für Klinische Pharmakologie, D-70376 Stuttgart, Germany (U.M.Z.)
| |
Summary |
|---|
|
|
|---|
Phenobarbital elicits pleiotropic effects in the liver, including
induction of enzymes involved in xenobiotic metabolism. The spectrum of
this response was analyzed by differential display of a large
population (~7500) of mRNAs in chicken embryo liver treated in
vivo with phenobarbital. We identified 29 cDNA fragments that
reproducibly and significantly changed in intensity after a 48-hr
in ovo treatment. Eighteen of these (62%) were
increased, whereas 11 (38%) were decreased. Twenty strongly regulated
cDNA fragments were subcloned and further analyzed. Nucleotide sequence analysis revealed three types of genes: (a) those previously described to be regulated by phenobarbital, including CYP2H1, glutathione S-transferase, and uridine
diphosphate-glucuronosyltransferase; (b) genes reported herein for the
first time to be regulated by phenobarbital, including fibrinogen
-chain and
-chain, retinal glutamine synthetase, apolipoprotein
B, two gene products with homologies to elongation factor 1
and
complement factor H, respectively, and (c) several novel genes with
hitherto unknown functions. If these data are extrapolated to the
entire population of mRNAs of a liver cell, phenobarbital seems to
significantly modulate the expression of more than 50 different genes.
Our results also demonstrate that a large fraction of genes is
negatively regulated by drug treatment.
| |
Introduction |
|---|
|
|
|---|
Several classes of environmental and therapeutic chemicals are recognized to modulate gene expression in liver but also in other tissues. In particular, the induction of genes coding for enzymes involved in the biotransformation and detoxification of drugs and chemicals is well known (1, 2). Among the inducing agents are polyaromatic and polychlorinated hydrocarbons, peroxisome proliferators such as clofibrate, glucocorticoids and antiglucocorticoids, alcohol, and numerous drugs and chemicals (3-5). Phenobarbital is the prototype inducer for a variety of other xenobiotic compounds called "phenobarbital-like," which exhibit inductive effects on different biotransformation enzymes including GSTs, UDP-glucuronosyl transferase, epoxide hydrolases, NADPH-cytochrome P450 reductase, aldehyde dehydrogenases, and several cytochrome P450 monooxygenases (2, 6, 7).
The response to phenobarbital is dose-dependent, reversible, and
accompanied by an increase in liver weight and proliferation of the
smooth endoplasmatic reticulum. More recent studies indicate that genes
not involved in drug metabolism may also be regulated by
phenobarbital-like compounds. These include
1-acid glycoprotein, apolipoprotein apo-A1, cholesterol 7
-hydroxylase, and a rat
canalicular glutathione transporter (8-11). The inductive response can
have a major impact on drug-drug interactions, toxicity, and
carcinogenicity of exogenous and endogenous compounds (for review, see
Refs. 2 and 4).
The molecular mechanisms of this induction phenomenon are still poorly understood. The best understood system is the phenobarbital induction of two fatty acid hydroxylases in Bacillus megaterium, in which induction involves inhibition of repression of the controlled genes by a repressor protein (12-15). Major obstacles to intensive investigation of mammalian mechanisms have been the apparent lack of a phenobarbital receptor as well as the lack of appropriate cell culture systems. The response seems to be largely controlled at the level of transcription, and, more recently, molecular analysis of phenobarbital regulated promoters and enhancer regions has been performed (16-20). Despite these recent advances, the way in which the cell recognizes phenobarbital and phenobarbital-like compounds and the way in which this information is conveyed to the transcriptional machinery remains a mystery.
The pleiotropic response to phenobarbital and phenobarbital-like compounds suggests that, in addition to drug-metabolizing enzymes, the expression of numerous other genes may be affected. The spectrum of altered gene expression, however, has not been studied systematically. Therefore, we investigated the extent and character of phenobarbital-mediated changes of gene expression in the liver. As a model system, we used the chick embryo because previous studies in our laboratory (21, 22) have demonstrated reliable induction of cytochromes P450 by phenobarbital and other inducers in primary cultures of chick embryo hepatocytes maintained under chemically defined conditions. These results have been confirmed by other investigators (23, 24). This system also allows investigations in vivo by direct injection of phenobarbital into the fluids surrounding the embryo (in ovo) (21).
In the present study, we used the recently developed differential display technique (25, 26) to analyze the effect of phenobarbital on the hepatic mRNA population of chicken embryos treated in ovo. We describe the isolation and sequences of 20 cDNAs influenced by phenobarbital detected by this method. Genes not previously known to be regulated by phenobarbital were discovered, and, surprisingly, a large number of genes were found to be down-regulated by phenobarbital.
| |
Materials and Methods |
|---|
|
|
|---|
White Leghorn fertilized eggs were obtained from
Geflügelzucht Gallipor AG, Ottenbach, Switzerland. Phenobarbital
(sodium salt) was obtained from the Hospital Pharmacy, University
Hospital, Zurich, Switzerland. Redivue
[
-35S]dATP (1000 Ci/mmol), [
-32P]dATP
(3000 Ci/mmol), and [
-32P]dATP (5000 Ci/mmol) were
purchased from the Radiochemical Center, Amersham International, Bucks,
England. All other chemicals were from standard commercial sources.
Moloney murine leukemia virus reverse transcriptase was purchased from
Gibco BRL/Life Technologies, Basel, Switzerland. Recombinant
ribonuclease inhibitor was obtained from Promega, Zurich, Switzerland.
All other enzymes were purchased from New England Biolabs, BioConcept,
Allschwil, Switzerland. PCR reactions were performed in a Perkin Elmer
Cetus (Rotkreuz, Switzerland) thermocycler using AmpliTaq DNA
polymerase also obtained from Perkin Elmer. PCR primers were purchased
from Intron Laboratory for Molecular Biology, Kaltbrunn, Switzerland.
Ten-mer oligonucleotides (Table 1) were selected from a
list of random sequences and checked for absence of stem loops and
self-complementarity of more than two nucleotides. A liver cDNA library
in
Zap Vector from a 7-day-old male broiler breeder chicken was
obtained from Stratagene, La Jolla, CA.
|
Induction in vivo.
For induction studies in
vivo (in ovo), direct injections of phenobarbital into
the fluids surrounding the embryo were performed. Phenobarbital (5 mg
per egg) was dissolved in 0.2 ml of 0.9% saline. Control animals were
injected with the same amount of 0.9% saline without phenobarbital.
For injection, the orientation of the embryo was marked using a small
intensive source of light. Injection was then performed with a 0.9-mm
needle and a 1-ml syringe into the yolk sac. Chicken embryo livers were
perfused through the heart with 20 ml of ice-cold 0.9% NaCl and 2 mM EDTA to remove blood cells. Livers were taken out and
frozen immediately in liquid nitrogen. If not used for immediate RNA
isolation, livers were stored at
80°.
RNA isolation. Isolation of total RNA was performed by the classical guanidinium thiocyanate method of Chomczynski and Sacchi (27). For each isolation, two livers were pooled (total of approximately 1 g of tissue) to overcome interindividual differences in differential display analysis.
Differential display.
One microgram of total RNA was reverse
transcribed using free nucleotides at a concentration of 200 µM. cDNA templates were diluted 1:10 for subsequent PCR
analysis. Differential display PCR was performed in the presence of 10 µCi [
-35S]dATP, 1.6 µM random 10-mer
and oligo-dTMN primer using 1 unit of Taq polymerase in
1 × reaction buffer containing 2 mM Mg2+,
2 µM free nucleotides, under the following conditions: 50 cycles of 94° for 30 sec, 40° for 60 sec, and 72° for 30 sec, and
one cycle of 72° for 5 min, followed by cooling to 4°. PCR products were ethanol-precipitated and resuspended in 10 µl of 1× loading buffer containing 90% formamide, 10% 10× Tris/borate/EDTA (1 × Tris/borate/EDTA is 90 mM Tris-borate, 2 mM
EDTA), bromphenol blue, and xylenecyanol. Samples were displayed on a
6% denaturing polyacrylamide gel. PCR fragments identified as
differentially regulated were confirmed by reverse transcription and
PCR using RNA isolated from independent induction experiments. PCR
fragments of interest were electro-eluted and used for PCR
reamplification using the same primer set and the same conditions as
described for differential display except that the free nucleotide
concentration was increased to 20 µM and no isotope was
added. PCR products were subcloned in pBluescript SK+
vector and sequenced (Sequenase Version 2.0; United States Biochemical, Cleveland, OH).
Northern analysis. Twenty micrograms of total RNA was subjected to electrophoresis on a formamide-containing 1% agarose gel. RNA was transferred to a nylon membrane (GeneScreen; New England Nuclear Research Products, Boston, MA) by blotting overnight in 20× SSC (1× = 150 mM NaCl, 15 mM sodium citrate). The membrane was baked in a vacuum oven for 2 hr at 80°. Hybridization was carried out in buffer containing 50% deionized formamide, 5× SSC, 5× Denhardt's solution, 1% SDS and 10% (w/v) dextransulfate. Before being added to the hybridization solution, the random labeled probe was boiled for 5 min in 500 µl of 10 mg/ml salmon sperm DNA and quickly chilled on ice. Hybridization was carried out for 16-20 hr. Washes were performed in 2× SSC/0.1% SDS at room temperature for 30 min and 2× SSC/1% SDS at 65° for 20 min. Membranes were exposed to X-ray film using intensifying screens or to PhosphorImager screens for 12-48 hr.
cDNA library screening. All manipulations were carried out according to the suppliers' protocols. Typically, 300,000 phages were plated on six large 15-cm Petri dishes. Replicas were made using nitrocellulose filters (BA85; Schleicher & Schuell, Riehen, Switzerland). After denaturing and neutralizing, the filters were baked in a vacuum oven at 80° for 2 hr. Prehybridization was performed for 2 hr at 42° in 0.02 M PIPES, pH 6.5, 0.8 M NaCl, 50% deionized formamide, 0.5% SDS, and denatured salmon sperm DNA at a final concentration of 100 µg/ml. The random-labeled probe was added directly to the prehybridization solution. Depending on the length of the probe, hybridization was carried out at different stringencies: 42° for longer fragments, 38° for shorter fragments. Washing conditions were set up as follows: 0.1 × SSC/0.1% SDS at 60° for 2 × 30 min for high stringency and 2 × SSC/0.1% SDS at 45° for low stringency. Washing conditions were for high stringency: 0.1 × SSC/0.1% SDS 2 × 30 min at 60° and for low stringency: 2 × SSC/0.1% SDS 2 × 30 min at 45°. Filters were exposed to X-ray film using intensifying screens for 12-24 hr. Positive clones were isolated and further purified in a secondary and tertiary screening. The pBluescript phagemid was excised in vivo using the EXASSIST/SOLR system provided with the cDNA library kit.
Computer sequence analysis. Nucleotide sequences were analyzed by comparison with the GenBank/EMBL nucleotide databases using the FASTA program (28) of the GCG sequence analysis package, version 7.0 (Madison, WI).
| |
Results |
|---|
|
|
|---|
Design and optimization of an internal control.
Because it is
known that phenobarbital strongly induces CYP2H1 mRNA in chick embryo
liver (21, 29), we first designed a nonrandom DDRT-PCR primer pair for
this gene product. Observation of the predicted 220-bp PCR product
allowed an efficient initial optimization of a number of parameters,
including length of the 5
primer, structure of the 3
oligo-dTMN
primer, RNA preparation, and PCR parameters (data not shown). Indeed,
the CYP2H1 product appeared as a strongly inducible signal under
optimized conditions (Fig. 1, lane 1).
Induction was highly reproducible when RNA from independent experiments
was used. The PCR product was excised from the polyacrylamide gel,
electro-eluted, reamplified, and subcloned. Sequence analysis confirmed
its identity. Furthermore, Northern blotting of liver mRNA using the
amplified product as a probe revealed an mRNA size of 3.5 kb and an
induction rate of ~55-fold (Fig. 2), which is in close
agreement with previously published data (30). This analysis confirmed
the validity of the technique to isolate phenobarbital-responsive
genes.
|
|
Effect of phenobarbital on chick embryo liver mRNA. A total of 25 arbitrary 10-mers combined with 6 of 12 possible oligo-dTMN primers were used to scan approximately 7500 mRNA species, given that an average of approximately 50 individual gene products were amplified and visualized by each pair of primers. The patterns obtained were highly specific for the primer pair used, and little variation was seen in repeated independent experiments. No bands were observed in negative control experiments when reverse transcription was omitted and PCR was performed as usual (data not shown). On the basis of reproducible and visually easily detectable intensity changes, a total of 29 DNA fragments were finally identified as being significantly regulated by the drug treatment. Of these, 18 fragments strongly increased, whereas 11 fragments decreased in intensity (Table 2).
|
Identification of regulated gene products.
Of the 29 regulated
cDNA fragments, 20 fragments were reamplified and subcloned for further
analysis. Nucleotide sequencing revealed that all of them were flanked
by sequences complementary to the PCR primers used. Only one product
(clone 12) was apparently generated by amplification with a single
10-mer priming at 5
and 3
positions, whereas all other products
originated as intended. Sequence analysis revealed that three isolated
fragments were identical (clones 4, 5, and 13; Table 2). These PCR
fragments had been amplified by the same random 10-mer (primer 6) in
combination with the three oligo-dTMA primers. This was the only
observed case of degeneracy of oligo-dTMN primers, whereas all other
isolated DNA fragments had distinct sequences and did not overlap with each other.
, respectively. Homologies of all other
fragments were either not significant or restricted to short fragments
within the PCR products.
Regulation of mRNA expression in vivo.
An important
consideration is the verification of the regulation of the identified
cDNA fragments by alternative methods (31). It was assumed that
Northern blots using these subcloned fragments as probe would permit us
to confirm the increase or decrease in the corresponding mRNA. However,
when fragments that were positioned directly in front of the
polyalanine tail were used, no signals were obtained on Northern blots.
It is possible that aminotransferase-rich sequences and the relatively
short fragments used as probes are at the root of this observation. We
therefore tried to circumvent this problem by directly screening a
chicken liver cDNA library using some of the DDRT-PCR fragments as
probes. If the isolated cDNA clones contained mainly coding sequences,
Northern blotting confirmed the regulation of the respective gene
(e.g., for UDP glucuronosyl-transferase). Thus, the differential
display method is indeed very sensitive for detecting regulated genes,
but confirmation by Northern blotting is not always possible. We also
observed that some of the PCR amplification products were generated
from annealing of the 3
primer within the coding sequence of a gene or
at a position upstream of the polyalanine tail in the 3
noncoding region (data not shown). Northern blotting reliably confirmed the
effect of phenobarbital on CYP2H1 mRNA by using the subcloned 220-bp
cDNA fragment as probe (Fig. 2, left lane). Regulation of
fibrinogen
-chain and complement factor H was also confirmed by
Northern analysis (Fig. 2, middle and right
lanes). The decrease in their expression after 48 hr in
vivo treatment by phenobarbital was determined to be 2.5- and
5.5-fold, respectively.
Screening of a chicken liver cDNA library.
Some of the
regulated PCR products were isolated, subcloned, and used to screen a
chicken liver cDNA library. Three hundred thousand recombinant phages
were plated and screened using these PCR fragments as probe. Sequence
analysis of isolated positive clones further identified one gene
(isolated with fragment 2; Table 2) as the
-chain of chick
fibrinogen and another clone (isolated with fragment 19) showed 65%
homology to rat fibrinogen
-chain. The cDNA isolated with fragment
12 showed 78% homology to human, murine, and rat UDP
glucuronosyl-transferases, enzymes known to be induced by phenobarbital
in other organisms (2, 32, 33). In all of these cases, the original
fragments produced by DDRT-PCR were located within the 3
noncoding
region but were located upstream of the polyalanine tail. These
sequences could not be identified directly because no sequence
information on these noncoding regions was contained in the databases.
Several cDNA clones representing other PCR products did not show
homology to known genes, which indicated that they were derived from
novel genes with as yet undefined functions. Partial sequences of these new genes are presented in Figure 3.
|
| |
Discussion |
|---|
|
|
|---|
The present study provides new information on the extent and complexity of the overall cellular response to the xenobiotic phenobarbital. Our data indicate that phenobarbital significantly affects the expression of presumably more than 50 genes in a liver cell at the transcriptional and/or post-transcriptional level. These data were generated by applying the mRNA differential display technique to chicken embryo liver treated with phenobarbital.
Only cDNA fragments reproducibly amplified in at least two independent experiments and showing at least a 2-fold change in density after phenobarbital treatment were considered for further analysis. Thus, if smaller changes are included, an even greater number of genes will emerge as being influenced by this drug. By using 150 primer combinations, of which each resulted in the display of at least 40-60 distinct bands, approximately 7,500 mRNA species were covered. This represents ~50% of the estimated 10,000-20,000 cellular mRNAs (34). Of the 27 different genes regulated by phenobarbital, 16 genes were up-regulated and 11 down-regulated.
Our first analysis was performed 48 hr after phenobarbital treatment because chicken CYP2H1 is maximally induced at this time and we wanted to analyze a sustained change in response. This time course of induction may not apply to other genes influenced by phenobarbital and, in particular, to those coding for transcription factors.
In addition to the CYP2H1 used as internal control, two genes already
known to be induced by phenobarbital were identified: GST and UDP
glucuronosyl-transferase. This finding demonstrated the suitability of
the DDRT-PCR technique and of our system. In addition, the
identification of genes already known but not described to be regulated
by phenobarbital opens the possibility to study their regulation in
comparison to genes whose regulations have been studied for many years
(e.g., cytochromes P450). Of major interest for systems affected by
phenobarbital are two clones with sequences revealing high homology to
human, rabbit, rat, and X. laevis sequences
complement
factor H and elongation factor 1
. The reported property of these
proteins to bind DNA (35, 36) indicate that the induction mechanism of
phenobarbital could involve regulation at different steps and that
probably more than a single trans-acting protein might be
involved. Complement factor H is a negative regulator of the
alternative pathway of the complement system. Earlier studies (35-37)
suggest that complement factor H and complement factor B are the two
major DNA-binding proteins of human serum. The question is whether
factor H may be one of the phenobarbital-modulated transcription
factors that trigger the induction of the other genes or just part of
the pleiotropic response. Elongation factor 1
catalyzes the
GTP-dependent binding of aminoacyl-tRNA to ribosomes during the
elongation step of prokaryotic protein synthesis. It has been shown
recently (38) that elongation factor 1
in Artemia sp. and
X. laevis possesses a leucine zipper, which suggests that
this motif is conserved and has a special function. It has also been
shown that elongation factor 1
is present in the nucleus (39) and
has a role in DNA replication (40). Our identification of known genes
not yet recognized to be regulated by phenobarbital and the
identification of new genes points to a more general effect of
phenobarbital on gene expression than previously recognized. The
regulated genes are not only involved in metabolic activities
(cytochromes P450, GST, UDP-glucuronosyl transferase) but are also part
of cellular defense mechanisms (complement factor H), translation
activities (elongation factor 1
), and blood clotting (fibrinogen).
Interestingly, the cellular response reveals not only induction but
also repression of a considerable number of genes. In fact, almost half
of the identified fragments (38%) were significantly repressed. These
results underline the complex and very subtle cellular response to
phenobarbital, which indicates a regulatory cascade at many different
levels of gene regulation.
In conclusion, our data reveal a much more profound change in gene expression in response to phenobarbital than that previously envisioned as restricted to a few drug-metabolizing enzymes. The further identification of the spectrum and time course of the extensive reported down-regulation of genes should allow insight into the initial molecular events associated with mediating the pleiotropic response to phenobarbital.
| |
Acknowledgment |
|---|
We are grateful to Ms. D. Marek for technical assistance.
| |
Footnotes |
|---|
Received August 28, 1996; Accepted November 11, 1996
1 Current affiliation: Department of Molecular Pharmacology, School of Medicine, Stanford University, Stanford, California 94305-5332.
This work was supported by the Swiss National Science Foundation.
Send reprint requests to: Urs A. Meyer, Ph.D., Department of Pharmacology, Biozentrum, Klingelbergstrasse 70, University of Basel, CH-4056 Basel, Switzerland. E-mail: meyer2{at}ubaclu.unibas.ch
| |
Abbreviations |
|---|
PCR, polymerase chain reaction;
GST, glutathione S-transferase;
SSC, standard saline citrate;
SDS, sodium dodecyl sulfate;
PIPES, piperazine-N,N
-bis(2-ethanesulfonic
acid);
bp, base pair(s);
dTMN, oligodeoxythymidine, where M is
guanosine, cytidine, or adenosine and N is guanosine, cytidine,
adenosine, or thymidine ;
dTMA, oligodeoxythymidine, where M is
guanosine, cytidine, or adenosine and A is adenosine;
DDRT-PCR, differential display of reverse transcribed mRNA amplified by the
polymerase chain reaction .
| |
References |
|---|
|
|
|---|
| 1. | Gonzalez, F. J. The molecular biology of cytochrome P450s. Pharmacol. Rev. 40:243-286 (1989)[Medline]. |
| 2. | Waxman, D. J. and L. Azaroff. Phenobarbital induction of cytochrome P-450 gene expression. Biochem. J. 281:577-592 (1992). |
| 3. | Adesnik, M. and M. Atchison. Genes for cytochrome P-450, and their regulation. Crit. Rev. Biochem. 19:247-305 (1986). |
| 4. | Okey, A. B. Enzyme induction in the cytochrome P-450 system. Pharmacol. Ther. 45:241-298 (1990)[Medline]. |
| 5. | Whitlock, J. P. The regulation of cytochrome P-450 gene expression. Annu. Rev. Pharmacol. Toxicol. 26:333-369 (1986)[Medline]. |
| 6. | Lechner, M. C., C. Sinogas, M. L. Osorio-Almeida, M. T. Freire, P. Chaumet-Riffaud, M. Frain, and J. M. Sala-Trepat. Phenobarbital-mediated modulation of gene expression in rat liver. FEBS Lett. 163:231-238 (1987). |
| 7. | Pinkus, R., S. Bergelson, and V. Daniel. Phenobarbital induction of AP-1 binding activity mediates activation of glutathione S-transferase and quinone reductase gene activation. Biochem. J. 290:637-640 (1993). |
| 8. | Fournier, T., N. Mejdoubi, D. Monnet, G. Durand, and D. Porquet. Phenobarbital induction of alpha 1-acid glycoprotein in primary rat hepatocyte cultures. Hepatology 20(6):1584-1588 (1994)[Medline]. |
| 9. | Tam, S. P. and R. G. Deeley. Regulation of apolipoprotein A-I gene expression by phenobarbital in the human hepatocarcinoma cell line, Hep3B. Atherosclerosis 105:235-243 (1994)[Medline]. |
| 10. | Sudjana-Sugiaman, E., G. Eggertsen, and I. Bjorkhem. Stimulation of HMG-CoA reductase as a consequence of phenobarbital-induced primary stimulation of cholesterol 7 alpha-hydroxylase in rat liver. J. Lipid Res. 35(2):319-27 (1994)[Abstract]. |
| 11. | Yi, J. R., S. Lu, J. Fernandez-Checa, and N. Kaplowitz. Expression cloning of a rat hepatic reduced glutathione transporter with canalicular characteristics. J. Clin. Invest. 93(4):1841-1845 (1994). |
| 12. |
Fulco, A. J.,
J. S. He, and
Q. Liang.
The role of conserved 5 flanking (Barbie Box) DNA sequences and barbiturate-responsive DNA-Binding proteins in the mechanism of induction by barbiturates of the P450 cytochromes in Bacillus megaterium and other prokaryotic and eukaryotic organisms, in Cytochrome P450: 8th International Conference (M. C. Lechner, ed.). John Libbey Eurotext, Paris, 37-42 (1994).
|
| 13. |
He, J. S. and
A. J. Fulco.
A barbiturate-regulated protein binding to a common sequence in the cytochrome P450 genes of rodents and bacteria.
J. Biol. Chem.
266:7864-7869 (1991) |
| 14. |
Shaw, G. C. and
A. J. Fulco.
Inhibition by barbiturates of the binding of bm3r1 repressor to its operator site on the barbiturate-inducible cytochrome P450BM- 3 gene of Bacillus megaterium.
J. Biol. Chem.
268:2997-3004 (1993) |
| 15. |
He, J. S.,
Q. Liang, and
A. J. Fulco.
The molecular cloning and characterization of BM1P1 and BM1P2 proteins, putative transcription factors involved in barbiturate-mediated induction of the genes encoding cytochrome P450NBM-1 of Bacillus megaterium.
J. Biol. Chem.
270:18615-18625 (1995) |
| 16. | Shephard, E. A., L. A. Forrest, A. Shervington, L. M. Fernandez, G. Ciaramella, and I. R. Phillips. Interaction of proteins with a cytochrome P450 2B2 gene promotor: identification of two DNA sequences that bind proteins that are enriched or activated in response to phenobarbital. DNA Cell Biol. 13:793-804 (1994)[Medline]. |
| 17. |
Upadhya, P.,
M. V. Rao,
V. Venkateswar,
P. N. Rangarajan, and
G. Padmanaban.
Identification and functional characterization of a cis-acting positive DNA element regulating CYP2B1/B2 gene transcription in rat liver.
Nucleic Acids Res.
20:557-562 (1992) |
| 18. |
Ramsden, R.,
K. M. Sommer, and
C. J. Omiecinski.
Phenobarbital induction and tissue-specific expression of the rat CYP2B2 gene in transgenic mice.
J. Biol. Chem.
268:21722-21726 (1993) |
| 19. |
Prabhu, L.,
P. Upadhya,
N. Ram,
C. S. Nirodi,
S. Sultana,
P. G. Vatsala,
S. A. Mani,
P. N. Rangarajan,
A. Surolia, and
G. Padmanaban.
A model for the transcriptional regulation of the CYP2B1/B2 gene in rat liver.
Proc. Natl. Acad. Sci. USA
92:9628-9632 (1995) |
| 20. |
Trottier, E.,
A. Belzil,
C. Stoltz, and
A. Anderson.
Localization of a phenobarbital-responsive element (PBRE) in the 5 flanking region of the rat CYP2B2 gene.
Gene
158:263-268 (1995)[Medline].
|
| 21. |
Althaus, F. R.,
J. F. Sinclair,
P. Sinclair, and
U. A. Meyer.
Drug-mediated induction of cytochrome(s) P-450, and drug metabolism in cultured hepatocytes maintained in chemically defined medium.
J. Biol. Chem.
254:2148-2153 (1979) |
| 22. |
Althaus, F. R. and
U. A. Meyer.
Effects of phenobarbital, -naphthoflavone, dexamethasone, and formamidoxime on the turnover of inducible microsomal proteins in cultured hepatocytes.
J. Biol. Chem.
256:13079-13084 (1981) |
| 23. | Hamilton, J. W., W. J. Bement, P. R. Sinclair, J. F. Sinclair, J. A. Alcedo, and K. E. Wetterhahn. Inhibition of protein synthesis increases the transcription of the phenobarbital-inducible CYP2H1 and CYP2H2 genes in chick embryo hepatocytes. Arch. Biochem. Biophys. 298:96-104 (1992)[Medline]. |
| 24. |
Mattschoss, L. A.,
A. A. Hobbs,
A. W. Steggless,
B. K. May, and
W. H. Elliott.
Isolation and characterization of genomic clones for two chicken phenobarbital-inducible cytochrome P-450 genes.
J. Biol. Chem.
261:9438-9443 (1986) |
| 25. |
Liang, P. and
A. B. Pardee.
Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction.
Science (Washington D. C.)
257:967-971 (1992) |
| 26. |
Liang, P.,
L. Averboukh,
K. Keyomarsi,
R. Sager, and
A. B. Pardee.
Differential display and cloning of messenger RNAs from human breast cancer versus mammary epithelial cells.
Cancer Res.
52:6966-6968 (1992) |
| 27. | Chomczynski, P. and N. Sacchi. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159 (1987)[Medline]. |
| 28. | Pearson, W. R. Rapid and sensitive sequence comparison with FASTP, and FASTA. Methods Enzymol. 183:63-98 (1990)[Medline]. |
| 29. |
Hahn, C. N.,
A. J. Hansen, and
B. K. May.
Transcriptional regulation of the chicken CYP2H1 gene.
J. Biol. Chem.
266:17031-17039 (1991) |
| 30. |
Hobbs, A. A.,
L. A. Mattschoss,
B. K. May,
K. E. Williams, and
W. H. Elliott.
The cDNA and protein sequence of a phenobarbital-induced chicken cytochrome P-450.
J. Biol. Chem.
261:9444-9449 (1986) |
| 31. |
Utans, U.,
P. Liang,
L. R. Wyner,
M. J. Karnovsky, and
M. E. Russell.
Chronic cardiac rejection. identification of five upregulated genes in transplanted hearts by differential mRNA display.
Proc. Natl. Acad. Sci. USA
91:6463-6467 (1994) |
| 32. | Kimura, T. and I. S. Owens. Mouse UDP glucuronosyltransferase. cDNA and complete amino acid sequence and regulation. Eur. J. Biochem. 168:515-521 (1987)[Medline]. |
| 33. | Mackenzie, P. I., N. R. Chowdhury, and J. R. Chowdhury. Characterization and regulation of rat liver UDP glucuronosyl transferase. Clin. Exp. Pharmacol. Physiol. 16:501-504 (1989)[Medline]. |
| 34. | Alberts, B., D. Bray, J. Lewis, M. Raff, K. Roberts, and J. D. Watson. Molecular Biology of the Cell. Garland Publishing, New York (1989). |
| 35. | Gardner, W. A., P. J. White, and S. O. Hoch. Identification of a major human serum DNA-binding protein as beta 1H of the alternative pathway of complement activation. Biochem. Biophys. Res. Commun. 94:61-67 (1980)[Medline]. |
| 36. |
Hoch, S. O. and
E. McVey.
Purification and characterization of two major DNA- binding proteins in human serum.
J. Biol. Chem.
252:1881-1887 (1977) |
| 37. | Gardner, W. D., J. A. Haselby, and S. O. Hoch. Identification of a major serum DNA-binding protein as factor B of the alternative complement pathway. J. Immunol. 124:2800-2806 (1980)[Abstract]. |
| 38. |
Amons, R.,
M. A. Guerrucci,
R. H. Karssis,
J. Morales,
P. Cormier,
W. Möller, and
R. Bellé.
The leucine zipper in elongation factor EF1 , a guanine-nucleotide exchange protein, is conserved in artemia and Xenopus.
Biochem. Biophys. Acta
1218:346-350 (1994)[Medline].
|
| 39. | Rao, M. S., L. I. Rothblum, and H. Busch. Presence of elongation factor 1 in nuclei and nucleoli of rat liver. Cell. Biol. Int. Rep. 2:25-32 (1978)[Medline]. |
| 40. | Kurasawa, K., O. Numata, M. Katoh, H. Hirano, J. Chiba, and Y. Watanabe. Identification of tetrahymena 14-nm filament-associated protein as elongation factor 1 alpha. Exp. Cell. Res. 203:251-258 (1992)[Medline]. |
This article has been cited by other articles:
![]() |
F. Rencurel, A. Stenhouse, S. A. Hawley, T. Friedberg, D. G. Hardie, C. Sutherland, and C. R. Wolf AMP-activated Protein Kinase Mediates Phenobarbital Induction of CYP2B Gene Expression in Hepatocytes and a Newly Derived Human Hepatoma Cell Line J. Biol. Chem., February 11, 2005; 280(6): 4367 - 4373. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Handschin and U. A. Meyer Induction of Drug Metabolism: The Role of Nuclear Receptors Pharmacol. Rev., December 1, 2003; 55(4): 649 - 673. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. de Longueville, F. A. Atienzar, L. Marcq, S. Dufrane, S. Evrard, L. Wouters, F. Leroux, V. Bertholet, B. Gerin, R. Whomsley, et al. Use of a Low-Density Microarray for Studying Gene Expression Patterns Induced by Hepatotoxicants on Primary Cultures of Rat Hepatocytes Toxicol. Sci., October 1, 2003; 75(2): 378 - 392. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Walter, C. Ullmann, D. Thummler, and W. Siegmund INFLUENCE OF PROPIVERINE ON HEPATIC MICROSOMAL CYTOCHROME P450 ENZYMES IN MALE RATS Drug Metab. Dispos., June 1, 2003; 31(6): 714 - 717. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Shibutani, N. Takahashi, T. Kobayashi, C. Uneyama, N. Masutomi, A. Nishikawa, and M. Hirose Molecular profiling of genes up-regulated during promotion by phenobarbital treatment in a medium-term rat liver bioassay Carcinogenesis, June 1, 2002; 23(6): 1047 - 1055. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ueda, H. K. Hamadeh, H. K. Webb, Y. Yamamoto, T. Sueyoshi, C. A. Afshari, J. M. Lehmann, and M. Negishi Diverse Roles of the Nuclear Orphan Receptor CAR in Regulating Hepatic Genes in Response to Phenobarbital Mol. Pharmacol., January 1, 2002; 61(1): 1 - 6. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Handschin, M. Podvinec, R. Looser, R. Amherd, and U. A. Meyer Multiple Enhancer Units Mediate Drug Induction of CYP2H1 by Xenobiotic-Sensing Orphan Nuclear Receptor Chicken Xenobiotic Receptor Mol. Pharmacol., October 1, 2001; 60(4): 681 - 689. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Handschin, M. Podvinec, J. Stockli, K. Hoffmann, and U. A. Meyer Conservation of Signaling Pathways of Xenobiotic-Sensing Orphan Nuclear Receptors, Chicken Xenobiotic Receptor, Constitutive Androstane Receptor, and Pregnane X Receptor, from Birds to Humans Mol. Endocrinol., September 1, 2001; 15(9): 1571 - 1585. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. BERNS, R. HUMAR, B. HENGERER, F. N. KIEFER, and E. J. BATTEGAY RACK1 is up-regulated in angiogenesis and human carcinomas FASEB J, December 1, 2000; 14(15): 2549 - 2558. [Abstract] [Full Text] |
||||
![]() |
C. Handschin and U. A. Meyer A Conserved Nuclear Receptor Consensus Sequence (DR-4) Mediates Transcriptional Activation of the Chicken CYP2H1 Gene by Phenobarbital in a Hepatoma Cell Line J. Biol. Chem., April 28, 2000; 275(18): 13362 - 13369. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Honkakoski, R. Moore, K. A. Washburn, and M. Negishi Activation by Diverse Xenochemicals of the 51-Base Pair Phenobarbital-Responsive Enhancer Module in the CYP2B10 Gene Mol. Pharmacol., April 1, 1998; 53(4): 597 - 601. [Abstract] [Full Text] |
||||
![]() |
J. Kim and B. Kemper Phenobarbital Alters Protein Binding to the CYP2B1/2 Phenobarbital-responsive Unit in Native Chromatin J. Biol. Chem., November 21, 1997; 272(47): 29423 - 29425. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Smirlis, R. Muangmoonchai, M. Edwards, I. R. Phillips, and E. A. Shephard Orphan Receptor Promiscuity in the Induction of Cytochromes P450 by Xenobiotics J. Biol. Chem., April 13, 2001; 276(16): 12822 - 12826. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||